Suven to acquire controlling stake in NJ Bio Inc.
Suven Pharmaceuticals Limited a technology-leading CDMO specializing in complex and innovative drug modalities, has announced the acquisition of a controlling stake in NJ Bio Inc. with an investment of USD 64.4 million.










